key: cord-0961695-0aeu9qz6
authors: Newell, Krista L.; Waldran, Mitchell J.; Thomas, Stephen J.; Endy, Timothy P.; Waickman, Adam T.
title: Simultaneous analysis of antigen‐specific B and T cells after SARS‐CoV‐2 infection and vaccination
date: 2022-05-05
journal: Cytometry A
DOI: 10.1002/cyto.a.24563
sha: 756cad8f5654b802b365b20ba2822563c3d648ba
doc_id: 961695
cord_uid: 0aeu9qz6

Conventional methods for quantifying and phenotyping antigen‐specific lymphocytes can rapidly deplete irreplaceable specimens. This is due to the fact that antigen‐specific T and B cells have historically been analyzed in independent assays each requiring millions of cells. A technique that facilitates the simultaneous detection of antigen‐specific T and B cells would allow for more thorough immune profiling with significantly reduced sample requirements. To this end, we developed the B and T cell tandem lymphocyte evaluation (BATTLE) assay, which allows for the simultaneous identification of SARS‐CoV‐2 Spike reactive T and B cells using an activation induced marker (AIM) T cell assay and dual‐color B cell antigen probes. Using this assay, we demonstrate that antigen‐specific B and T cell subsets can be identified simultaneously using conventional flow cytometry platforms and provide insight into the differential effects of mRNA vaccination on B and T cell populations following natural SARS‐CoV‐2 infection.

The identification, quantification, and characterization of antigenspecific lymphocytes is a critical prerequisite for understanding the breadth, magnitude, and functional potential of vaccine and/or natural pathogen-elicited immunity. Multiple distinct methodologic approaches have been developed that allow for the identification of antigen-specific T and B cells. For the identification of antigen-specific T cells, these include quantification of functional cytokine-producing T cells by ELISPOT, flow cytometric detection of intracellular cytokine production following peptide stimulation, staining with peptide/HLA probes, and upregulation of activation-induced markers following antigen engagement [1] [2] [3] [4] [5] [6] . Analogous approaches have also been developed for the identification of antigen specific B cells including, but not limited to, B cell ELISPOT assays and the use of fluorescently conjugated protein probes to stain antigen-specific B cells [7] [8] [9] [10] . However, a major limitation of the approaches developed thus far is that they interrogate rare B and T cell subsets in isolation. An approach capable of identifying and phenotyping antigen-specific B cells, CD4 + T cells, and CD8 + T cells simultaneously would preserve valuable samples by performing multiple assays in parallel, making the assessment of B and T cells that recognize the same antigen more efficient.

In this study, we endeavored to simultaneously identify and characterize SARS-CoV-2 spike protein-specific B cells, CD4 + T cells, and CD8 + T cells in the same Peripheral Blood Mononuclear Cell (PBMC) sample. We used the combination of an Activation-Induced Marker (AIM) assay to identify spike reactive T cells following stimulation with overlapping spike peptide pools, and spike reactive B cells by baiting with dual spike trimer fluorescent tetramers. This approach was then used to quantify and longitudinally track the T and B cell populations induced by natural SARS-CoV-2 infection and subsequent SARS-CoV-2 mRNA vaccination in the same individuals. Flow cytometric analysis of these antigen-specific populations revealed that while the spike-specific B cell, and to lesser degree CD8 + T cell responses, were consistently enhanced by mRNA vaccination, a clear boosting effect on spike-specific CD4 + T cells was only detectable in individuals with low or undetectable T cell responses following natural infection. Furthermore, we validated our observations of SARS-CoV-2-specific B cell functional enhancement upon vaccination with paired serological analysis. Our findings suggest divergent patterns of B and T cell subset mobilization with repeated antigen encounter and highlight the utility of examining these populations in concert.

PBMC and sera for this study were obtained from the previously described SUNY Upstate Medical University Convalescent COVID-19

Plasma Donor protocol [11, 12] . Samples used in this study were collected between April 22, 2020 and June 17, 2021. A subset of 10 donors was selected for focused analysis in the study using the following criteria: (1) blood collection at least 30 days after but not longer than 75 days after their last COVID-19 symptom,

(2) immunization with two doses of a SARS-CoV-2 mRNA vaccine at least 9 months after a negative polymerase chain reaction (PCR) test (8/10 Pfizer-BioNTech, 2/10 Moderna mRNA-1273), and (3) blood collection at least 30 days, but not longer than 22 weeks following vaccination. One subject was excluded from the final analysis due to immunosuppressive treatment for autoimmune disease at the time of sample collection. Archived sera and PBMC from healthy individuals collected prior to December 2019 were used as negative controls.

Sample size was determined based on subject availability and conformity of sample collection to the described timeline.

Full-length SARS-CoV-2 Spike (2P-stabilized, C-terminal Histidine/ Avi-tagged) was obtained from BEI resources (Manassas, VA, Cat. NR53524) and biotinylated using a BirA ubiquitin ligase (Avidity, Aurora, CO, Cat. Bir500A) following the manufacturer's recommended protocol. Biotinylated spike protein was purified using a 40 K molecular weight cut-off (MWCO) 2 ml Pierce Zeba™ desalting column (Thermo Fisher Scientific, Waltham, MA, Cat. 87768), and mixed with streptavidin BV421 (BD, Cat. 563259) or streptavidin allophycocyanin (APC) (BD Cat. 554067) separately at a 20:1 ratio (~6:1 molar ratio) as previously described [3] . Tetramerized Spike probes were stored at 4 C until use. Just prior to probe staining, spike protein probes were added one-by-one to FACS wash buffer (1x PBS, 2% fetal bovine serum) containing 5 μM free d-biotin (Avidity, Cat. Bir500A). Both streptavidin-fluor conjugates were used to stain dimethyl sulfoxide (DMSO) control samples to further verify the absence of significant frequencies of nonspecific streptavidinbinding B cells.

Spike-specific T cells were quantitated as a frequency of AIM + (OX40 + CD69 + ) CD4 + T or (CD25 + CD69 + ) CD8 + T cells among PBMC following 24 h of stimulation with overlapping peptide pools covering the length of SARS-CoV-2 spike peptide (BEI, Cat. NR52402), as previously described [11] . Cryopreserved PBMC were thawed, washed twice, and cultured in complete cell culture media: RPMI 1640 medium 

All participants provided written informed consent prior to participation in the study, which was performed according to protocols approved by the Institutional Review Board (IRB) of the SUNY Upstate Medical University under IRB number 1587400 for experimental samples and 1839296-1 for pre-pandemic control samples. All clinical investigation was conducted according to Declaration of Helsinki principles.

Study design and assay workflow schematics were created with BioRender.com.

We developed an assay workflow ( Figure 1A ) for the simultaneous detection of SARS-CoV-2 spike-specific T and B cells from cryopreserved PBMC. Cryopreserved PBMC were thawed and stimulated for 24 h with overlapping peptide pools spanning SARS-CoV-2 spike to stimulate SARS-CoV-2 spike protein-reactive T cells, followed by incubation with fluorescent spike trimer tetramers to bait spikebinding B cells. These steps were followed by staining with fluorescent antibodies and viability dye prior to interrogation by flow cytometry or sorting. The gating strategy for flow cytometry is illustrated in Figure S1 .

Using this approach, we were able to identify and quantify SARS-CoV-2 spike-reactive B cells ( Figure 1B ) in tandem with conventional activation-induced marker (AIM) T cell stimulation using as few as 3 Â 10 6 PBMC per sample from SARS-CoV-2 mRNA vaccine recipients.

Notably, overnight culture or stimulation with overlapping peptide pools did not significantly interfere with the detection of antigen-specific B cells using fluorescent spike B cell probes, although a modest but statistically insignificant reduction was observed between cells stained fresh from cryopreservation and overnight culture with DMSO or peptide pools ( Figure 1C ). Our results demonstrate that B and t cell tandem lymphocyte evaluation (BATTLE) is an efficient assay capable of simultaneously quantifying and isolating antigen-specific B and T cells from a single PBMC sample.

To demonstrate the utility of our new approach, we used the BATTLE assay to examine the impact of SARS-CoV-2 mRNA vaccination on spike protein-specific adaptive immunity following natural infection.

We selected a cohort of subjects from a large study of convalescent plasma donors who experienced symptomatic but mild infection and had a peripheral blood draw between 30 and 75 days of symptom resolution (Figure 2A ). This window was selected to capture the profile of antigen-specific memory lymphocytes proximally to natural infection, but following resolution of acute inflammatory responses to infection. We included subjects who were vaccinated with two doses of mRNA vaccine at least 9 months following a negative SARS-CoV-2 PCR test and had a subsequent blood draw more than 30 days, but no more than 22 weeks following vaccination. These time constraints were chosen to ensure that immune memory was stable prior to vaccination, and to capture the profile of antigen-specific memory lymphocytes proximally to vaccination, but following resolution of acute vaccine-driven inflammation.

To validate and extend the clinical utility of our findings, we evaluated the serological profiles of each donor from the same visits used in the BATTLE assay. As expected, IgG against the SARS-CoV-2 nucleocapsid protein, which is induced by natural infection but not mRNA vaccination, declined between the first and postvaccination samples, while anti-N IgM was largely below the level of reliable detection ( Figure 2B ,C). Serum anti-spike receptor-binding domain (RBD) IgG, but not IgM, responses also were enhanced by mRNA vaccination ( Figure 2D,E) . Additionally, IgG, but not IgM, raised against the spike RBD from SARS-CoV-2 variant strains alpha and beta was significantly enhanced following mRNA vaccination, although not all subjects had equally improved variant reactivity ( Figure S2 ).

To determine if SARS-CoV-2 mRNA vaccination had an impact on the B cell response targeting spike protein, we examined spike-reactive B 3.4 | SARS-CoV-2 mRNA vaccination differentially impacts the spike-specific peripheral CD4 + and CD8 + T cell compartments following natural infection We next sought to determine whether spike-reactive CD4 + and CD8 + T cells within the same PBMC vial were similarly enhanced by mRNA vaccination after natural SARS-CoV-2 infection. We quantified the expression of activation-induced markers on these T cell subsets and found that, unlike for B cells targeting spike protein, the frequency of CD4 + spike peptide-activated T cells was not significantly enhanced following mRNA vaccination compared with infection alone ( Figure 3B,E) . Although significant changes were not observed for the full cohort, the frequency and number of AIM + CD4 + T cells was increased following vaccination for some individuals, particularly for those with a lower initial spike-specific adaptive response. The same trend was observed for subjects with low AIM + CD8 + T cell frequencies following natural infection, but unlike the spike-specific CD4 + T cell compartment, CD8 + T cells reactive to spike were marginally enhanced in frequency following mRNA vaccination ( Figure 3C,F) . The same patterns were present when adjusting for the number of cells used as input for the assay, although for AIM + CD8 + T cells differences between the groups no longer reached statistical significance ( Figure S3b,c) . As observed for spike-specific B cells, few AIM + T cells were present in PBMC samples collected prior to the onset of the SARS-CoV-2 pandemic, and unlike T cells from exposed subjects, those from pre-SARS-CoV-2 samples were largely unresponsive to spike peptide pool stimulation ( Figure S3b was only significant for the original SARS-CoV-2 strain. These results propose a coordinated response to SARS-CoV-2 between B cells and CD8 + T cells, potentially without sustained synchronization with the CD4 + T cell compartment. Taken together, these data suggest that mRNA vaccination of previously infected individuals influences T cell subsets asymmetrically, and may allow those who mount a suboptimal response to infection to achieve an immunological set point not reached via natural infection.

Here we demonstrate that B cells and CD4 + and CD8 + T cells specific for the same antigen can be simultaneously identified and quantified in a single PBMC sample. Furthermore, our results suggest that the ability for SARS-CoV-2 spike-specific B and T cells to be enhanced by Although our study was limited to the examination of PBMC, it is possible that these observations extend to other sources of lymphocytes, such as lymph node aspirates, bronchioalveolar lavage fluid, and bone marrow. Antigen-specific lymphocytes have been identified within these specimens in humans and non-human primates [17] [18] [19] , suggesting that BATTLE can be applied to maximize the yield of information gathered from these valuable samples. Although AIM assays can be performed with as few as 1 Â 10 6 PBMC per well (3 Â 10 6 including controls) [3, 20] , the detection of antigen-specific B cells can utilize 1-1.2 Â 10 7 PBMC per sample [3, 21] , with this number varying considerably based on the expected frequency of the population.

Thus, BATTLE can reduce the number of PBMC required to detect both antigen-specific B and T cells by up to 12 million PBMC.

Unlike other studies, we did not detect substantial frequencies or numbers of SARS-CoV-2 spike-binding T cells in nonexposed individuals [22, 23] . We also did not detect SARS-CoV-2 cross-reactive B cells at appreciable frequencies in pre-pandemic controls, as has been suggested by serological studies from other groups [24, 25] . We attribute these disparities between our observations and others' potentially to demographic variability between our sampling region and populations and those sampled in other studies. It is also possible that the sensitivity of our assay was lower, although we consider this unlikely to be the case, as the quantities of antigen-specific T cells we observed postinfection and postvaccination were well-aligned with those in the literature [3, 26] .

The observation of increased quantities of spike-specific B cells following mRNA vaccination after natural infection supports the idea that mRNA vaccination is beneficial even after natural adaptive immunity has developed. Additionally, our results suggest that spikereactive B cells may possess a capacity for vaccine-elicited expansion beyond that of spike-reactive CD4 + T cells. The mechanism by which this process may occur is still an active area of investigation, but an attractive hypothesis is that B and T cell populations each achieve an independent immunological set point following resolution of acute infection or vaccine-induced activation. As the epitopes recognized by B cells, CD4 + T cells, and CD8 + T cells, the timing, and settings in which these events occur, and the environmental signals these population receive can differ considerably, it is tempting to speculate that uncoordinated dynamic expansion and contraction of B and T cells can lead to the generation of immunological memory in a compartmentalized manner. This interpretation would be supported with recent work describing coordinated and timely B and T cell responses that lead to the generation of superior adaptive immunity, and importantly that the lack thereof can have pathological consequences [27] [28] [29] . BATTLE is an ideal approach that can be harnessed to explore these concepts.

There are some important limitations to the use of BATTLE worth additional consideration. Our study did not exclude the writingreview and editing (supporting).

Phenotypic analysis of antigen-specific T lymphocytes

A cytokine-independent approach to identify antigen-specific human germinal center T follicular helper cells and rare antigen-specific CD4 + T cells in blood

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Direct access to CD4+ T cells specific for defined antigens according to CD154 expression

Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

Techniques to study antigenspecific B cell responses

A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells

Demonstration that antigenbinding cells are precursors of antibody-producing cells after purification with a fluorescence-activated cell sorter

Antigen-specific B cell detection reagents: use and quality control

Persistent COVID-19 symptoms minimally impact the development of SARS-CoV-2-specific T cell immunity

Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

Adaptive immunity to SARS-CoV-2 and COVID-19

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Divergent SARS CoV-2 omicron-reactive T-and B cell responses in COVID-19 vaccine recipients

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity

Delayed production of neutralizing antibodies correlates with fatal COVID-19

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Compromised humoral functional evolution tracks with SARS-CoV-2 mortality

Simultaneous analysis of antigen-specific B and T cells after SARS-CoV-2 infection and vaccination

Stephen J. Thomas reports compensation from Pfizer, during the conduct of the study; personal fees from Merck, Sanofi, Takeda, Themisbio, and Janssen, outside the submitted work. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.